-
SkIN Canada NewsSkIN Canada News
-
-
-
-
Featured profiles
-
-
-
From the SkIN Canada Training Committee Hub
-
-
-
-
News from Other Organizations
-
-
-
-
-
Recent Publications by SkIN Canada Members
-
-
-
-
-
Summer 2024
Team Development Awards
1. Objective
This funding opportunity aims to support preliminary activities for developing novel teams and the infrastructure necessary to conduct future multicentre research for the benefit of patients living with skin conditions.
2. Description
The Skin Investigation Network of Canada (SkIN Canada) is offering a funding opportunity to facilitate collaborative research that benefits people living with skin conditions. Funded by the Canadian Institutes of Health Research (CIHR) – Institute of Musculoskeletal Health and Arthritis, SkIN Canada has three main goals: a) develop national infrastructure to advance multicentre skin research; b) foster new collaborations between patients, researchers, and clinicians at academic and community sites; and c) grow the skin research community. We recognize the value of open science and patient engagement to achieve these goals, and have ensured that the patient voice is integrated throughout all our activities.
In accordance with the network’s mission, SkIN Canada will be funding a series of awards to catalyze novel multicentre skin research. These grants are intended to support preliminary activities that are typically not fundable as stand-alone projects. For example, operating grants usually require preliminary work and validated infrastructure to demonstrate feasibility and potential for success.
Deadline: October 15, 2024
Recap of SkIN Canada at the Canadian Skin Research Conference


The Canadian Skin Canada Research Conference represented the first joint meeting of the Skin Investigators Network of Canada (SkIN Canada), Skin Research Group of Canada (SRGC), Canadian Dermatology Foundation (CDF), Canadian Skin Patient Alliance (CSPA), and Canadian Society for Investigative Dermatology (CSID), which was held in conjunction with the 99th Canadian Dermatology Association (CDA) Annual Conference in Otttawa on June 25-27.
- 115 Attendees
- 2 Keynote presentations
- 26 abstract presentations
- 52 new member sign-ups
Congratulations to Monika Winnicki for winnning our Name a Trial Competition. The top-ranked idea was to evaluate Oral JAK inhibitor on people with Lichen Palnus and compare it to Acitretin or phototherapy in reducing the number and thickness of lesions, quality of life measures, and itch reduction. Congratulations Dr. Winnicki!
SkIN Canada has also held an inaugural Skin of Colour Working Group meeting to establish future activities of the working group in addition to a Translational Research Committee meeting to organize the activities of that committee.
Dr. Maryam Piram

Dr. Maryam Piram is is a French pediatric dermatologist specializing in conditions that intersect dermatology and rheumatology. Dr. Piram earned her medical degree in 2006 after completing a 3-year residency in pediatrics followed by a 2-year residency in dermatology.
She then pursued two fellowships: one in pediatric rheumatology at CHU Bicêtre (University of Paris Sud) in France (2006-2009) and another in pediatric dermatology at CHU Sainte-Justine (University of Montreal) in Canada (2010-2011). In 2010, she obtained an MPH degree from University Paris 12, and in 2017, she earned a PhD from University Paris Sud, focusing on the epidemiology of IgA vasculitis. Dr. Piram is currently an associate professor in the pediatric dermatology department at CHU Sainte-Justine in Montréal, Canada (University of Montreal), and at the French national reference center for auto-inflammatory diseases (CéReMAIA) at CHU de Bicêtre in Kremlin-Bicêtre, France (University Paris Saclay, Paris Sud). Her primary research areas are childhood vasculitis and auto-inflammatory diseases.
Team Development Award Project Title: Auto-inflammatory skin diseases: creation of a Canadian Network (SkinSAIDCanada)
Lay Abstract: SkinSAIDCanada is a project about rare diseases, called autoinflammatory diseases, that make people’s bodies have too much inflammation. The skin can show signs of these diseases, making it like a window to seeing what’s happening inside the person’s body. But, doctors who see people for the skin problem may not know much about these rare diseases. Our project aims bring together expert doctors, researchers, and patients living with these diseases and the organizations that support them to learn more about the skin manifestations in autoinflammatory diseases and better help patients. We will collect information from multiple centers across Canada and aim to better characterize the cutaneous manifestations in these rare diseases. The goals are to help doctors recognize and better manage patients with these conditions, assess the frequency and distribution of these diseases in the Canadian population, describe current access to care and management, identify unmet needs and create a resource for patients and families on skin manifestations of these diseases.
Scientific Summary: Systemic autoinflammatory diseases (SAIDs) are a group of rare disorders characterized by dysregulation of the innate immune system resulting in recurrent inflammation affecting multiple organs, including the skin. These lifelong conditions, which cause various skin manifestations, have a significant impact on patients and families. Due to the rarity of these diseases, dermatologists’ limited familiarity with the skin manifestations of SAIDs can lead to misdiagnosis and inadequate treatment. The SkinSAIDCanada project involves physicians, researchers, patients and patient advocates focused on improving the understanding and management of SAIDs-related skin conditions. Goals include 1) establishing a Canadian network of dermatologists and experts in SAIDs and skin science, 2) creating a multicenter database to describe the epidemiology of these conditions, current access to care and management, and to identify unmet needs in Canada, and 3)developing educational materials for both physicians and patients. Our network will facilitate collaborative research through a multicenter approach to rare diseases. Standardized data collection using REDCap® will enable robust analyses. The physician clinical awareness strategy aims to increase early diagnosis, improve patient care and engage new stakeholders. Patient education materials will empower patients and their families with evidence-based information and engagement opportunities. A study of skin manifestations in SAIDs will enable the identification of unique patterns of skin involvement, stimulating diagnostic and therapeutic advances (biomarkers, targeted therapies, new mutations…).Led by Dr. Piram, the multidisciplinary team combines expertise in SAIDs, clinical research and patient engagement. Overcoming challenges to network development, such as stakeholder engagement and multicenter ethics approval and contracting, is critical and SkINCanada funding will address these initial barriers. In summary, our proposal aims to create a collaborative platform that will revolutionize SAIDs research and care in Canada. Our network envisions a comprehensive approach to improving the understanding and management of skin manifestations of SAIDs in Canada.
Dr. Timothy Hanna

Dr. Timothy Hanna is a clinician scientist at the Division of Cancer Care and Epidemiology, Cancer Research Institute at Queen’s University, Kingston, Ontario, Canada. He is also a radiation oncologist at the Cancer Centre of Southeastern Ontario. His work focuses on health services research in oncology, with three translational streams: quality of care, value of care and access to care. His value of care research touches on health technology assessment in the real-world, particularly for novel therapies (e.g. radiotherapy, ‘omics driven personalized medicine, immunotherapy). Methods include machine learning approaches, and often use large, complex data sets.
He received his PhD and Fellowship training at the Collaboration for Cancer Outcomes Research and Evaluation (CCORE) at Liverpool Hospital in Sydney, Australia (2010-2012). He developed models of population benefit of optimal radiotherapy utilization as part of his PhD thesis work and fellowship there, working with Prof M Barton, Prof G Delaney and Dr. J Shafiq. Prior to this, he trained at Queen’s University in Radiation Oncology and completed an MSc with Dr. WJ Mackillop, focusing on barriers to access to radiation and its impact on cancer outcomes for endometrial cancer. Dr. Hanna obtained his MD at the University of Toronto.
Team Development Award Project Title: A Multi-Province Platform for Merkel cell carcinoma Health Services Research.
Lay Abstract: Skin cancer is the most common type of cancer in Canada. It is important to know how skin cancer is cared for in Canada, in order to ensure the best care is provided for every person with skin cancer in Canada. We are making a team of researchers and patient partners that will develop tools to allow experts to study this topic. We are going to study Merkel cell carcinoma in order to develop these tools. Because Merkel cell carcinoma is rare, it is especially important to study this cancer using as many sources of information from across Canada as possible. We will do this first in Ontario, Alberta and British Columbia. The tools we develop to do this, and the team that we will build during this work will help us do this same sort of information collection across Canada. The knowledge gained through our initial work in Ontario, Alberta and British Columbia will help us apply for research funding to do this, and to develop research projects involving people from across Canada with other forms of skin cancer, and even other skin diseases
Scientific Summary: Merkel cell carcinoma is a rare but deadly skin cancer. It is not well-captured in cancer registries, making population-based studies of the epidemiology and health service utilization for Merkel cell carcinoma difficult. As a result, little is known about the quality of care, and outcomes, of Merkel cell carcinoma in Canada. We have assembled a team of researchers and patient research partners to develop the tools that are needed to address this topic. We propose to develop the tools needed to collect information across Canada on Merkel cell carcinoma care in Canada. Because Merkel cell carcinoma is rare, but often lethal, it is especially important to study this cancer using data from across Canada. This ensures there is adequate study power to appropriately address health services research questions. We plan to undertake tool development for a research platform first in Ontario, Alberta and British Columbia. Our research team has extensive experience working with linked health administrative data sources and cancer registry data in these settings. The tools we develop during this platform development exercise, and the team we will build during this work will help us to undertake similar data collection at the pan-Canadian level. The knowledge gained through our initial work in Ontario, Alberta and British Columbia will help us apply for grant funding to undertake this, and to develop further research projects on Merkel cell carcinoma.
Early Career Investigator

Dr. Rachel Asiniwasis is a dermatologist and early career clinician researcher based in western Canada (her hometown of Regina, Saskatchewan). She is the founder of Origins Dermatology Centre, a combined multidisciplinary model that services both the general population and provides outreach clinics (in-person and virtual care) for underserviced remote and rural Indigenous (First Nations and Metis) communities. Rachel is of Plains Cree, Saulteaux and English background. She carries a Master’s of Science in Health Sciences in clinical and translational research, and has special interest in common inflammatory dermatoses (atopic dermatitis, psoriasis), virtual care, underserviced areas, holistic impact of skin disease, medical education, and translational interpretation and implementation of research with the ultimate goal of tangible health outcomes. She currently has active educational and research projects ongoing in the areas of inflammatory skin disease, virtual care, and Indigenous and rural health in western Canada.
Patient Research Partner

My name is Latoya Palmer, I am a Child and Youth Counselor who specializes in mental health. I have had HS for over 20 years and have been through various medical treatments and multiple surgeries. Due to my experience with HS especially with my most recent surgery, I have grown the desire to bring more awareness to HS. I have created the “Hidradenitis & Me” Support Group as a step to allow ourselves to begin to heal, take our life back, and to end the quiet storm of feeling alone through our journey.
Latoya is a member of the SkIN Canada Translational Research Committee.
Can SkIN Canada help?
Request support for your study
SkIN Canada has launched a formal study intake process for investigators requesting support from the Network. Please visit our RESOURCES page for more information on how we can help with funding, patient engagement, database creation, project administration, ethics application, or statistical support.
Skin Canada Travel and Mobility Awards – Application Deadline October 15, 2024
1. Travel Award: The deadline for the next SkIN Canada Trainee Travel Award is Tuesday October 15 (2024) before 11:59 PM ET. SkIN Canada provides partial funding for trainees to attend conferences as part of their training experience. A limited number of awards are available each year on a competitive basis. There are two competition periods per year, one in May and one in October. Applicants who have previously received funding through this program in a fiscal year are not eligible to receive funding until the following fiscal year. The value of the SkIN Canada Travel Award is a maximum of $1,000 CAD.
2. Mobility Award: The deadline for the next SkIN Canada Trainee Mobility Award is Tuesday October 15 (2024) before 11:59 PM ET. The SkIN Canada Trainee Mobility Award provides funding for trainees in the field of skin research to study and conduct research for a brief period in a laboratory other than their own within Canada or abroad as part of their training experience. A limited number of awards are available each year on a competitive basis. There will be two competition periods per year, one in May and one in October. Applicants are eligible for the award only once during a particular training period or level of study (e.g. MSc, PhD, Clinical residency, or Postdoctoral training).
The value of the Skin Canada Trainee Mobility Award is up to $4,000 which can be used for the trainee’s research in a laboratory other than their own, within Canada or abroad for a period ranging from 2 weeks to 6 months.
Skin Canada Training Committee Opening
The Training Committee represents skin research trainees from across Canada. The Committee considers representations from across Canada to be valuable. The committee currently has an opening for a PhD student or a post-doctoral fellow from any of the Western Provinces. If interested in joining this dynamic committee, please send your expression of interest and CV to info@skincanada.org.
CIHR Planning and Dissemination Grants – Oral Health
(Summer 2024 Competition)

Call for Applications: CADR-NCOHR Student Research Awards 2024-25


The Canadian Association for Dental Research (CADR) and the Network for Canadian Oral Health Research (NCOHR) announce a Call for Applications for the CADR-NCOHR Student Research Awards (2024-25).
These awards will be available for trainees to present their research at the AADOCR/CADR meeting in New York, New York, USA, March 12-15, 2025.
Applications must be submitted no later than Tuesday, September 3, 2024. Please see Call for Applications for further details.
For further information, you may contact:
Iona Worden-Driscoll | BSc, MBA
National Coordinator, Network for Canadian Oral Health Research
Healthy Populations Institute
Dalhousie University
1318 Robie Street, Halifax, NS B3H 3E2
2024 NCOHR Summer Institute

The Network for Canadian Oral Health Research is pleased to announce the successful applicant of our 2024 Summer Institute Program. Dr. Hollis Lai, School of Dentistry, University of Alberta will lead the organization and hosting of the Applied AI in Oral Health Summer Institute.
This summer institute will focus on applied and methodological AI training through examples and the application of coding techniques to solve challenges in dental research. This program is designed for interested dental researchers and students with no previous experience in AI who wish to pursue this dimension of research. The program is scheduled to take place for four days from July 23 to 26, 2024. It will offer active learning sessions in the morning and labs with hands-on, project-based learning using Google Colab in the afternoon.
Event Link: Click HERE
Registration Link: https://forms.gle/bfPuC5rFGKwkQwb99. An NCOHR-sponsored travel subsidy may be available.. Details can be found on the registration form.
For further information, you may contact:
Iona Worden-Driscoll, MBA, BSc
National Coordinator, Network for Canadian Oral Health Research
Healthy Populations Institute
Dalhousie University
1318 Robie Street, Halifax, NS B3H 3E2
Eczema Society of Canada Research Grant Program

The Eczema Society of Canada (ESC) is dedicated to improving the lives of Canadians living with eczema by providing support, education, and raising awareness. ESC’s Research Grant Program provides an opportunity for Canadian researchers to apply for funding for research and/or eczema education projects. Grant amounts range up to $25,000 per grant.
ESC is pleased to invite Canadian researchers to apply today for this funding opportunity. Please help them spread the word! Applications may include research and/or educational projects that will work toward improving the lives of eczema sufferers here in Canada.
The Application Deadline is September 1, 2024.
1. Silverberg JI, Gooderham M, Katoh N, Aoki V, Pink AE, Binamer Y, Rademaker M, Fomina D, Gutermuth J, Ahn J, Valenzuela F, Ameen M, Steinhoff M, Kirchhof MG, Lio P, Wollenberg A. Combining treat-to-target principles and shared decision-making: International expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. J Eur Acad Dermatol Venereol. Jul 11 2024.https://www.ncbi.nlm.nih.gov/pubmed/38989857
2. Wheeler KE, Chu DK, Schneider L. Updated Guidelines for Atopic Dermatitis-AAAAI/ACAAI Joint Task Force. JAMA Pediatr. Jul 8 2024.https://www.ncbi.nlm.nih.gov/pubmed/38976275
3. Chu X, Wang J, Ologundudu L, Brignardello-Petersen R, Guyatt GH, Oykhman P, Bernstein JA, Saini SS, Beck LA, Waserman S, Moellman J, Khan DA, Ben-Shoshan M, Baker DR, Oliver ET, Sheikh J, Lang D, Mathur SK, Winders T, Eftekhari S, Gardner DD, Runyon L, Asiniwasis RN, Cole EF, Chan J, Wheeler KE, Trayes KP, Tran P, Chu DK. Efficacy and Safety of Systemic Corticosteroids for Urticaria: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. J Allergy Clin Immunol Pract. Jul 2024;12(7):1879-1889 e1878.https://www.ncbi.nlm.nih.gov/pubmed/38642709
4. Ushcatz I, Zhao HJ, Tadrous M, Aoki V, Chang AY, Dlova N, Merilleno ASP, Drucker AM. Association of Countries’ Atopic Dermatitis Burden and Sociodemographic Index with Topical Calcineurin Inhibitor Utilization. Dermatitis. Jul 3 2024.https://www.ncbi.nlm.nih.gov/pubmed/38959123
5. Li K, Bouadi N, Jeremian R, Bi WG, Piguet V, Croitoru DO. A Comparative Analysis of Hidradenitis Suppurativa and Acne Inversa Webpages. Clin Exp Dermatol. Jul 3 2024.https://www.ncbi.nlm.nih.gov/pubmed/38959433
Wound Healing, Fibrosis and Regeneration
1. Arif S, Larochelle S, Trudel B, Gounou C, Bordeleau F, Brisson AR, Moulin VJ. The diffusion of normal skin wound myofibroblast-derived microvesicles differs according to matrix composition. J Extracell Biol. Jan 2024;3(1):e131.https://www.ncbi.nlm.nih.gov/pubmed/38938680
2. Arif S, Richer M, Larochelle S, Moulin VJ. Microvesicles derived from dermal myofibroblasts modify the integrity of the blood and lymphatic barriers using distinct endocytosis pathways. J Extracell Biol. May 2024;3(5):e151.https://www.ncbi.nlm.nih.gov/pubmed/38939570
3. Rijal H, Bouadi N, Piguet V, Mukovozov I. Treatment Outcomes of Scleroderma With Janus Kinase Inhibitors: A Systematic Review. J Cutan Med Surg. Jun 10 2024:12034754241260021.https://www.ncbi.nlm.nih.gov/pubmed/38859662
4. Safoine M, Paquette C, Gingras GM, Fradette J. Improving Cutaneous Wound Healing in Diabetic Mice Using Naturally Derived Tissue-Engineered Biological Dressings Produced under Serum-Free Conditions. Stem Cells Int. 2024;2024:3601101.https://www.ncbi.nlm.nih.gov/pubmed/38737365
5. Attiogbe E, Larochelle S, Chaib Y, Mainzer C, Mauroux A, Bordes S, Closs B, Gilbert C, Moulin VJ. An in vitro autologous, vascularized, and immunocompetent Tissue Engineered Skin model obtained by the self-assembled approach. Acta biomaterialia. Sep 15 2023;168:361-371.https://www.ncbi.nlm.nih.gov/pubmed/37419164
Skin Cancer
1. Narod SA, Metcalfe K, Finch A, Chan AW, Armel SR, Aeilts A, Eisen A, Karlan B, Bordeleau L, Tung N, Foulkes WD, Neuhausen SL, Eng C, Olopade O, Zakalik D, Couch F, Cullinane C, Pal T, Sun P, Kotsopoulos J, Hereditary Breast Cancer Clinical Research G. The risk of skin cancer in women who carry BRCA1 or BRCA2 mutations. Hered Cancer Clin Pract. May 13 2024;22(1):7.https://www.ncbi.nlm.nih.gov/pubmed/38741145
2. Ituarte BE, Taylor MA, Thomas SI, Ehsan E, Griffin J, Fernandez JM, Wei EX. Analysis of increasing prevalence of skin of colour publications in the PubMed database. J Eur Acad Dermatol Venereol. May 11 2024.https://www.ncbi.nlm.nih.gov/pubmed/38733280
3. Blanchard M, Morren MA, Busschots AM, Hauben E, Alberti-Violetti S, Berti E, Avallone G, Tavoletti G, Panzone M, Quaglino P, Colonna C, Melchers RC, Vermeer MH, Gniadecki R, Mitteldorf C, Gosmann J, Stadler R, Jonak C, Oren-Shabtai M, Hodak E, Friedland R, Gordon E, Geskin LJ, Scarisbrick JJ, Mayo Martinez F, Noguera Morel L, Pehr K, Amarov B, Faouzi M, Nicolay JP, Kempf W, Blanchard G, Guenova E. Paediatric onset lymphomatoid papulosis: results of a multicentre retrospective cohort study, on behalf of the EORTC Cutaneous Lymphoma Tumours Group (CLTG). The British journal of dermatology. Apr 10 2024.https://www.ncbi.nlm.nih.gov/pubmed/38595050
4. Huang Y, Fleming P, Fung K, Chan AW. Association between dermatology follow-up and melanoma survival: a population-based cohort study. J Am Acad Dermatol. Feb 16 2024.https://www.ncbi.nlm.nih.gov/pubmed/38368952
5. Venables ZC, Gran S, Levell NJ, Yiu ZZN, Proby CM. International melanoma and non-melanoma skin cancer mortality trends – is it time to re-focus our attention? Clin Exp Dermatol. Dec 7 2023.https://www.ncbi.nlm.nih.gov/pubmed/38060677
Skin of Colour
1. Scheufele CJ, Wong CM, Nguyen DA, Carletti M, Weis SE. Presentations of Cutaneous Disease in Various Skin Pigmentations: Seborrheic Dermatitis. HCA Healthc J Med. 2024;5(2):97-102.https://www.ncbi.nlm.nih.gov/pubmed/38984223
2. Lim H, Wong CM, Scheufele CJ, Nguyen DA, Carletti M, Weis SE. Presentations of Cutaneous Disease in Various Skin Pigmentations: Porokeratosis. HCA Healthc J Med. 2024;5(2):113-123.https://www.ncbi.nlm.nih.gov/pubmed/38984231
3. Nguyen C, Thompson J, Nguyen DA, Wong CM, Scheufele CJ, Carletti M, Weis SE. Presentations of Cutaneous Disease in Various Skin Pigmentations: Chronic Atopic Dermatitis. HCA Healthc J Med. 2024;5(2):103-111.https://www.ncbi.nlm.nih.gov/pubmed/38984232
4. Litaiem N, Sboui K, Daghrir J, Khouladi A, Tlig L, Bouchouicha M, Sayadi M, Zeglaoui F. Collective human intelligence vs. artificial intelligence: a comparative analysis for melanoma diagnosis in darker skin tones. Int J Dermatol. Jul 4 2024.https://www.ncbi.nlm.nih.gov/pubmed/38965055
5. Salmen NL, Curtis DP, Baumann AN, Willets J, Brodell RT. Skin color reporting in basal cell carcinoma-related randomized controlled trials in top dermatology journals: a systematic review. Arch Dermatol Res. Jul 5 2024;316(7):451.https://www.ncbi.nlm.nih.gov/pubmed/38967663
1. Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hrobjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria C, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH, 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration. BMJ. Jul 9 2024;386:e078525.https://www.ncbi.nlm.nih.gov/pubmed/38981624
2. Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hrobjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria C, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH, 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. BMJ. Jul 9 2024;386:e078524.https://www.ncbi.nlm.nih.gov/pubmed/38981645
3. Khalaf F, Ricciuti Z, Barayan D, Wojtowicz-Piotrowski S, Jeschke MG. Post-burn endocrine-immune dynamics and ageing considerations. Nat Rev Endocrinol. Jul 9 2024.https://www.ncbi.nlm.nih.gov/pubmed/38982289
4. McDermid A, Lam K, Ko YCK, Schmitt T, Khosravi-Hafshejani T, Dutz JP. Cyclosporin als Erstlinienbehandlung bei SARS‐CoV‐2‐reaktiver infektiöser mukokutaner Eruption bei Erwachsenen. J Dtsch Dermatol Ges. Jul 2024;22(7):1013-1015.https://www.ncbi.nlm.nih.gov/pubmed/38978425
5. Abdi P, Haq Z, Diaz MJ, Maibach HI, Ogunyemi B. Rosacea as a potential risk factor for dementia. Int J Dermatol. Jun 17 2024.https://www.ncbi.nlm.nih.gov/pubmed/38887091
SkIN Canada Executive Committee



